Mayo Clinic Identifies Diverse Zombie Cell Types to Target Aging

Mayo Clinic Studies Detail Diverse Senescent Cell Populations and Mitochondrial Leaks

Forty men and forty women aged 20 to 90 provided blood samples for a Mayo Clinic study tracking IL-23R protein levels as a biomarker of biological aging. The research forms part of seven recent studies exploring how senescent cells, often called zombie cells, drive inflammation and tissue dysfunction across different organs. The findings show that these non-dividing cells vary significantly by tissue and biological pathway, moving the field toward targeted measurement rather than blanket cellular destruction.

The Tech TL;DR:

• Seven new studies from the Mayo Clinic reveal that senescent zombie cells vary widely by tissue type and origin pathway, requiring precise identification tools rather than wholesale clearance.
• Researchers identified leaking mitochondrial DNA and RNA as a primary driver of inflammation, activating immune sensors like RIG-I and MDA5 through pores opened by BAX and BAK proteins.
• Preclinical trials in aged mice showed that tomatidine, a compound derived from tomatoes, successfully improved cognition and reduced brain inflammation.

SenMayo Gene Sets and Mitochondrial Pathways Drive Cellular Aging

Senescent cells stop dividing while remaining metabolically active, releasing inflammatory molecules that accumulate with age. Spotting these populations has historically presented a major obstacle in aging research. The Mayo Clinic team addressed this by establishing the SenMayo gene set, which provides a consistent framework to identify senescent cells across various tissues and experimental models. Additional papers from the group define distinct senotypes and compare p16- and p21-positive cells across human and mouse tissues.

This body of work is moving the aging field forward to precisely identify, understand and target the specific senescent cells that contribute to age-related dysfunction, which is the necessary groundwork to develop new therapies that support healthy aging.

Malfunctioning mitochondria compound this cellular stress by leaking genetic material into the main body of the cell. In studies tracking these mechanisms, mitochondrial RNA escaped through pores formed by BAX and BAK proteins, subsequently triggering viral immune sensors such as RIG-I and MDA5. A study published in Nature Communications linked this exact pathway of leaking mitochondrial RNA to severe fatty liver disease, demonstrating a mechanism that operates beyond the scope of chronological aging alone. Alongside this leakage, altered mitochondrial metabolism increases acetyl-CoA production, establishing epigenetic changes that prime inflammatory genes for activation.

Biomarkers and Preclinical Interventions in Aged Models

To track these cellular shifts without waiting decades for clinical disease outcomes, the research team evaluated IL-23R as a quantifiable blood biomarker. In human blood samples spanning ages 20 to 90, concentrations of the protein rose alongside chronological age. In murine models, IL-23R tracked senescence markers within aged organs, particularly the kidneys, and decreased following treatment with senotherapeutic drugs designed to clear or modify zombie cells.

Other experimental interventions tested in aged mice included genetic approaches, senolytic drugs, and tomatidine, a natural compound found in tomatoes. These treatments reduced measures of frailty, decreased brain inflammation, and improved cognitive performance. Mapping work associated with the NIH-funded Cellular Senescence Network (SenNet) further detailed senescent and disease-linked microglia residing in the white matter of aged mouse brains. None of these therapeutic interventions have advanced to human clinical trials.